Medical Therapy Guidelines
Jump to navigation
Jump to search
|
Endocarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
|
Case Studies |
|
Medical Therapy Guidelines On the Web |
|
Risk calculators and risk factors for Medical Therapy Guidelines |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Medical Therapy
| Class I |
| "1. Appropriate antibiotic therapy should be initiated and continued after blood cultures are obtained with guidance from antibiotic sensitivity data and infectious disease consultants(Level of Evidence: B)" |
| Class IIa |
| "1. It is reasonable to temporarily discontinue anticoagulation in patients with IE who develop central nervous system symptoms compatible with embolism or stroke regardless of the other indications for anticoagulation (Level of Evidence: B)" |
| Class IIb |
| "1. Temporary discontinuation of VKA anticoagulation might be considered in patients receiving VKA anticoagulation at the time of IE diagnosis (Level of Evidence: B)" |
| Class III (Harm) |
| "1. Patients with known VHD should not receive antibiotics before blood cultures are obtained for unexplained fever. (Level of Evidence: C)" |